

A randomised open label placebo study to evaluate the use of Solcogyn applied topically to the cervix in women referred for the assessment of cervical low grade intra-epithelial lesions

Submission date 12/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 12/09/2003	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 30/04/2015	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Miss Karen Easton

Contact details
Advanced Nurse Practitioner-Gynaecology
Russet Ward
Orchard Centre
Gloucestershire Royal Hospital
Great Western Road
Gloucester
United Kingdom
GL1 3NN

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0106110085

Study information

Scientific Title

A randomised open label placebo study to evaluate the use of Solcogyn applied topically to the cervix in women referred for the assessment of cervical low grade intro-epithelial lesions

Study objectives

To determine if treatment of a cervical ectopy associated with minor cytological abnormalities but no colposcopic evidence of high grade dysplasia results in a better clearance rate in terms of normal cytology at 6 month follow up than in the placebo controlled group.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised open-label placebo study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Dysplasia

Interventions

1. Placebo (saline)
2. Solcogyn

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Solcogyn

Primary outcome measure

Increased number of patients returning to normal cytology after six months of treatment.

Secondary outcome measures

Not provided at time of registration

Overall study start date

19/03/2002

Completion date

19/09/2003

Eligibility

Key inclusion criteria

106 women aged 20-50 attending the colposcopy clinic with cytological abnormalities showing borderline or mild changes and who also have a cervical ectopy.

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

106

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

19/03/2002

Date of final enrolment

19/09/2003

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Gloucestershire Royal Hospital
Gloucester
United Kingdom
GL1 3NN

Sponsor information

Organisation
Department of Health (UK)

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
<http://www.doh.gov.uk>

Funder(s)

Funder type
Government

Funder Name
Gloucestershire Research and Development Consortium (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration